Alagebrium chloride
Alagebrium chloride is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 3 | 1 | — | — | 3 |
| Aging | D000375 | GO_0007568 | R41.81 | — | 1 | 1 | — | — | 1 |
| Exercise | D015444 | EFO_0000483 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | 3 | — | — | — | 3 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 3 | — | — | — | 3 |
| Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | 2 | — | — | — | 2 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | 1 | — | — | — | 1 | |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
| Ventricular function | D016276 | — | 1 | — | — | — | 1 | ||
| Left ventricular hypertrophy | D017379 | EFO_0003896 | — | 1 | — | — | — | 1 | |
| Dyspnea | D004417 | HP_0002094 | R06.0 | — | 1 | — | — | — | 1 |
| Pulmonary edema | D011654 | EFO_1001134 | J81 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ALAGEBRIUM CHLORIDE |
| INN | alagebrium chloride |
| Description | Alagebrium (formerly known as ALT-711) was a drug candidate developed by Alteon, Inc. It was the first drug candidate to be clinically tested for the purpose of breaking the crosslinks caused by advanced glycation endproducts (AGEs), thereby reversing one of the main mechanisms of aging. Through this effect Alagebrium is designed to reverse the stiffening of blood vessel walls that contributes to hypertension and cardiovascular disease, as well as many other forms of degradation associated with protein crosslinking. Alagebrium has proven effective in reducing systolic blood pressure and providing therapeutic benefit for patients with diastolic heart failure.
|
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1sc[n+](CC(=O)c2ccccc2)c1C.[Cl-] |
Identifiers
| PDB | — |
| CAS-ID | 341028-37-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107309 |
| ChEBI ID | — |
| PubChem CID | 216306 |
| DrugBank | — |
| UNII ID | 79QS8K2877 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 141 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more